Release News
The pharmaceutical industries in the US and Europe are facing severe financial constraints which are expected to worsen in the years ahead. The pharma companies are under increasing pressure to reduce expenditure due to, the increasing cost of introducing a NME (New Molecular Entities) (more than $3 billion in 2008), tightening FDA regulatory issues, blockbuster drugs worth more than $100 billion set to expire by 2014 and drying pipelines These pressures are expected to drive the companies towards low-cost countries such as India and China to perform their R&D activities, one of their major expenses.
Over the last decade, India and China have developed significant capabilities in drug discovery research along with considerable capabilities in phase I & II clinical trials. Both countries are able to provide significant cost savings in the range of 60–70% for discovery research and clinical trials. With discovery research occupying close to one-third of the R&D expenditure for the Western pharmaceutical industry, outsourcing to low-cost countries is logical.
Â
For more information please click or add the below link to your browser:
Â
While the Indian and Chinese drug discovery companies have developed major service capabilities, many of the companies have also defined their therapeutic research focus. Analysis of 12 Indian and 10 Chinese companies research portfolios reveal that inflammatory diseases (18 companies), metabolic disorders (18) and cancer (16) are the top three therapeutic areas Other major therapy areas include anti-infectives and CNS (Central Nervous System). Major inflammatory disease research includes; COPD (Chronic Obstructive Pulmonary Disease), RA (Rheumatoid Arthritis), psoriasis, osteoarthritis, ulcerative colitis and atherosclerosis. However, at the country level the therapeutic focus is found to be different. Indian companies have concentrated their efforts on metabolic disorders; primarily diabetes, obesity and dyslipidemia. Chinese companies have focused on oncology; primarily leukemia, cervical cancer, breast cancer and prostrate cancer.
Â
For more information please click or add the below link to your browser:
Â
GBI Research, the leading business intelligence provider, has released its latest report, “Drug Discovery in India and China - Gaining Momentum with Increasing Pressure on Cost Cuttingâ€. It provides key data, information and analysis of the major trends and issues affecting the drug discovery market in India and China. The report provides a comprehensive insight into the drug discovery process and the model followed by the companies providing such services. The report also provides a detailed analysis of the factors that are driving the drug discovery market in India and China. The report talks about the key regulations, especially with respect to intellectual property rights protection, and how these regulations have benefited drug discovery companies in these two nations. The study analyses key partnerships between the local companies in the two countries and their western counterparts and the key trends emerging out of such partnerships. It also provides an insight into the government support initiatives in these countries to encourage the drug discovery research. This research provides a comparative analysis of the two countries and the major differences between India and China when it comes to drug discovery
Â
For more information please click or add the below link to your browser:
Â
Or visit our report store: http://www.globalbusinessintelligence.com
